Archive | Conferences

Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma

Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

Blocking tumor signals can hinder cancer’s spread

For most people who die of cancer, the spread of the initial tumor is to blame. “Metastasis is what kills most cancer patients,” says Serge Fuchs, a professor in Penn’s School of Veterinary Medicine. “Yet there are not many, if any, drugs that specifically target metastatic processes.”

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

Long-Term Biologic Use May Not Raise Melanoma Risk

NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis.

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma

Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Read the full story

Posted in Melanoma News, Health Professionals, Conferences